Last reviewed: July 1, 2026
Last updated: July 1, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The choice between semaglutide (Ozempic) and tirzepatide (Mounjaro) matters for weight loss outcomes. Both medications activate GLP-1 receptors in the brain to reduce hunger and slow digestion, but tirzepatide adds a second mechanism by targeting GIP receptors—a difference that changes how your body responds to treatment.
How Semaglutide and Tirzepatide Work Differently
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a natural hormone that signals your brain to feel full and satisfied. This single-pathway approach has decades of diabetes research backing its safety profile. When you take semaglutide, hunger hormones decrease and your stomach empties more slowly, creating a sustained sense of fullness throughout the day.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptors simultaneously. This dual-action mechanism addresses appetite control through two different neural pathways in the brain. The addition of GIP targeting may enhance weight loss by working on metabolic regions that semaglutide alone does not reach as effectively.
Clinical Weight Loss Results: Semaglutide vs Tirzepatide
Semaglutide studies show average weight loss of 15% of body weight over 68 weeks in patients with obesity. The STEP trials demonstrated consistent results across diverse populations, with most patients achieving meaningful weight reduction within 12 to 16 weeks of treatment. Response rates are predictable, making semaglutide a reliable first-line option for many patients.
Tirzepatide trials (SUMO-4 and SUMO-3) demonstrated average weight loss of 20% to 22% of body weight at the highest maintenance dose over comparable timeframes. Some patients in tirzepatide studies achieved weight loss exceeding 25% of their starting weight. The dual-pathway activation may account for these numerically higher averages, though individual responses vary significantly based on genetics and lifestyle factors.
Side Effects and Tolerability Profiles
Both medications cause similar gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation are most common during the dose-escalation phase. Nausea typically peaks in the first 4 weeks and decreases as your body adapts. Serious side effects like pancreatitis or gallbladder issues are rare but require immediate medical attention if they occur.
Tirzepatide users report slightly higher rates of nausea during dose increases compared to semaglutide, according to clinical trial data. However, many patients tolerate tirzepatide well once stable dosing is reached. Individual side effect severity depends on your starting dose, escalation speed, and genetic factors that influence how your body metabolizes GLP-1 pathway medications.
Which Medication Is Right for You: Genetics, Cost, and Access
PlexusDx offers both compounded semaglutide injection (starting at $149/mo) and tirzepatide injection (starting at $249/mo) from licensed 503A compounding pharmacies, with no insurance required and HSA/FSA eligibility. Your dose may need to go up. Your price won't. The Precision Peptide Genetic Test ($99 add-on) identifies your genetic predispositions in the GLP1R, GIPR, FTO, and MC4R pathways—insights that help predict which medication's dual or single-pathway approach aligns with your metabolic profile.
Response to GLP-1 therapy varies based on variants in GLP1R (rs6923761) and GIPR (rs1800437) genes. Patients with specific GIPR variants may experience enhanced appetite suppression from tirzepatide's GIP-targeting component, while those with certain GLP1R variants respond well to semaglutide's single-pathway approach. PlexusDx maps 14 pathways across 49 peptides to guide medication selection beyond trial data, ensuring your treatment matches your genetic reality rather than population averages.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does tirzepatide cause more weight loss than semaglutide in all patients?
Clinical trials show tirzepatide averages 20-22% weight loss versus semaglutide's 15%, but individual results vary significantly. Your genetics, diet, exercise, and metabolic factors determine your personal outcome. PlexusDx Precision Peptide Genetic Testing can reveal which medication's mechanism aligns better with your peptide-pathway genetics.
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
Yes, switching is medically appropriate and relatively common when weight loss plateaus. Your prescriber can transition you gradually to avoid side effects. The dual GIP-GLP-1 mechanism of tirzepatide may jumpstart results if your body has adapted to semaglutide's single-pathway approach.
How much does PlexusDx charge for tirzepatide, and does price change with dose?
PlexusDx compounded tirzepatide injection starts at $249/mo flat, regardless of dose level. Your dose may need to go up. Your price won't. All medications ship from licensed 503A compounding pharmacies to all 50 states with no membership fee or insurance requirement.
Is compounded semaglutide or tirzepatide as safe as brand-name versions?
PlexusDx medications are compounded by licensed 503A pharmacies, which operate under strict FDA oversight and quality standards. While not FDA-approved as brand names, compounded versions contain identical active pharmaceutical ingredients and undergo the same safety testing as brand products.
What does the Precision Peptide Genetic Test tell me about semaglutide vs tirzepatide?
The test ($99 add-on) analyzes variants in GLP1R, GIPR, FTO, and MC4R—genes that influence appetite regulation and metabolic response. Specific GIPR variants predict stronger response to tirzepatide's GIP-targeting action, while GLP1R variants correlate with semaglutide efficacy, guiding personalized treatment selection.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Staying on Low-Dose Ozempic: Long-Term Strategies and Considerations
What Are the Zepbound Doses for Effective Weight Management?